Expression of CD19/CD73 in Chronic Lymphocytic Leukemia and Its Correlation with Clinical Features.
10.19746/j.cnki.issn.1009-2137.2025.05.006
- Author:
Yan-Yu WANG
1
;
Lan LIU
1
;
Yu-Jie ZHAO
1
;
Geng-Hui SHI
2
;
Xun MIN
1
Author Information
1. Department of Laboratory, The Affiliated Hospital of Zunyi Medical University, Zunyi 563003 , Guizhou Province, China.
2. Department of Hematology, The Affiliated Hospital of Zunyi Medical University, Zunyi 563003 , Guizhou Province, China.
- Publication Type:Journal Article
- Keywords:
CD19/CD73;
chronic lymphocytic leukemia;
diagnosis;
splenomegaly;
clinical feature
- MeSH:
Humans;
Leukemia, Lymphocytic, Chronic, B-Cell/metabolism*;
5'-Nucleotidase/metabolism*;
Antigens, CD19/metabolism*;
Retrospective Studies;
Male;
Female;
Prognosis;
Middle Aged;
Aged;
Adult;
GPI-Linked Proteins
- From:
Journal of Experimental Hematology
2025;33(5):1274-1278
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the expression of CD19/CD73 in chronic lymphocytic leukemia (CLL) and its correlation with clinical features.
METHODS:The clinical data of 60 CLL patients and 40 healthy volunteers (control group) from January 2022 to November 2023 were retrospectively analyzed. The levels of CD19 and CD73 in peripheral blood of CLL patients were measured by flow cytometry. Kaplan-Meier method was used for survival analysis.
RESULTS:The hemoglobin (Hb) and CD19/CD73 levels in CLL group were significantly lower than those in control group, while CD19, CD73 and β2-MG were significantly higher (all P <0.001). According to ROC curve analysis, the AUC value of CD19/CD73 for CLL diagnosis was 0.980 (95%CI : 0.949-1.000, P <0.05), the specificity was 92.50%, and the sensitivity was 98.30%. The CD19/CD73 level of CLL patients with splenomegaly was significantly lower than those without splenomegaly (P <0.01). There was no significant correlation between CD19/CD73 and Hb in CLL patients ( r =0.056, P >0.05). CD19/CD73 was positively correlated with β2-MG ( r =0.837, 95%CI : 0.740 2-0.899 6, P <0.01). According to the median value (12.84) of CD19/CD73, the patients were divided into high and low expression groups. Kaplan-Meier survival analysis showed that the overall survival rate and progression-free survival rate at 18th month in the low expression group were 87.08% and 93.25%, while those in the high expression group were 96.41% and 99.90%, respectively (both P <0.05).
CONCLUSION:The level of CD19/CD73 is low in CLL patients, which can be used as an auxiliary index for clinical diagnosis of CLL. CD19/CD73 is closely related to splenomegaly in CLL patients. Low expression of CD19/CD73 predicts poor prognosis.
